Bryn Mawr Trust CO Cogent Biosciences, Inc. Transaction History
Bryn Mawr Trust CO
- $5.51 Billion
- Q2 2025
A detailed history of Bryn Mawr Trust CO transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Bryn Mawr Trust CO holds 730 shares of COGT stock, worth $8,000. This represents 0.0% of its overall portfolio holdings.
Number of Shares
730
Previous 730
-0.0%
Holding current value
$8,000
Previous $4,000
25.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding COGT
# of Institutions
193Shares Held
117MCall Options Held
62KPut Options Held
223K-
Kynam Capital Management, LP Princeton, NJ9.11MShares$99.8 Million4.6% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY8.96MShares$98.2 Million2.75% of portfolio
-
Commodore Capital LP New York, NY8.89MShares$97.5 Million5.22% of portfolio
-
Black Rock Inc. New York, NY7.29MShares$79.9 Million0.0% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA6.96MShares$76.3 Million10.05% of portfolio
About Cogent Biosciences, Inc.
- Ticker COGT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,758,300
- Market Cap $721M
- Description
- Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...